| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
biomarker quantification
with high-fat high-sucrose diet |
Bile acids in feces. | DO population | both | 4-26wks | 2018 |
|
|
body weight
with high-fat high-sucrose diet |
Weekly. | DO population | both | 4-26wks | 2018 |
|
|
colony observation
with high-fat high-sucrose diet |
Number of days on high-fat high-sucrose diet. | DO population | both | 4-26wks | 2018 |
|
|
DXA
with high-fat high-sucrose diet |
Bone mineral density. Isolated tibia. | DO population | both | 4-26wks | 2018 |
|
|
glucose tolerance
with high-fat high-sucrose diet |
Area under curve. | DO population | both | 4-26wks | 2018 |
|
|
hormone quantification
with high-fat high-sucrose diet |
Plasma insulin, adiponectin, leptin. Ex vivo insulin secretion. | DO population | both | 4-26wks | 2018 |
|
|
intake monitoring
with high-fat high-sucrose diet |
Food intake. Weekly. | DO population | both | 4-26wks | 2018 |
|
|
lipid profile
with high-fat high-sucrose diet |
Triglyceride. | DO population | both | 4-26wks | 2018 |
|
|
metabolic panel
with high-fat high-sucrose diet |
Glucose, HOMA-IR, HOMA-B. | DO population | both | 4-26wks | 2018 |
|
|
microscopy
with high-fat high-sucrose diet |
Number of islets harvested. | DO population | both | 4-26wks | 2018 |
|
|
organ weights
with high-fat high-sucrose diet |
Heart, liver, gonadal fat pads. | DO population | both | 4-26wks | 2018 |
|
|
study archive | Spontaneous diseases. | inbred | both | 2013 | |
|
|
body weight | Body weight | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
light-dark box | Anxiety, avoidance behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
nociception assay | Hot plate. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
open field test | Locomotor activity, exploratory, anxiety-related behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
tail suspension test | Frequency climbing, time immobile, latency immobile. 5 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
visual cliff | Anxiety, avoidance behavior. 20 min test. | DO population w/par (9) | both | 12-16wks | 2013 |
|
|
conditioned place preference test | In novel zone: exploration counts, entrance counts, time spent, activity counts, movement counts. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
hole board test | Number of entries, novel entries, and repeat entries. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
in vitro assay | Circadian parameters in fibroblast cultures: period, amplitude, phase, damping rate, goodness of fit. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
light-dark box | Distance traveled, ambulatory time and counts, resting time, stereotypic time and counts, jumping time and counts, vertical time and counts, time in light/dark. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
open field test
with cocaine |
Distance traveled, habituation ratio, number of rears, ambulatory time, time in perimeter, corners, and center; cocaine sensitization. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
operant conditioning chamber
with cocaine |
Number of infusions, active lever presses, inactive lever presses, intravenous self administration, reversal learning. | CC w/CC8 (61) | both | 4-25wks | 2021 |
|
|
hole board test
with cocaine |
Exploratory behavior. 10 min test. | DO population | both | 12-16wks | 2015 |
|
|
monitoring system
with cocaine |
Novelty preference test (preference for novel side vs. familiar side). 10 min test. | DO population | both | 12-16wks | 2015 |
|
|
open field test
with cocaine |
Locomotor activity and exploratory behavior. 20 min test. | DO population | both | 12-16wks | 2015 |
|
|
operant conditioning chamber
with cocaine |
Intravenous self-administration of cocaine via activation of levers. | DO population | both | 12-16wks | 2015 |
|
|
body weight | Body weight | DO population | both | 8-60 wks | 2020 |
|
|
bone dimensions | 3D, craniofacial landmark coordinates based on centroid. | DO population | both | 8-60 wks | 2020 |
|
|
nociception assay | Formalin injection. | DO population | both | 13-17wks | 2019 |
|
|
body weight | Body weight | DO population | m | 12-15wks | 2020 |
|
|
histopathology | Male reproductive histopathology. Percent normal, abnormal sperm. | DO population | m | 12-15wks | 2020 |
|
|
microscopy | Sperm motility | DO population | m | 12-15wks | 2020 |
|
|
organ weights | Male reproductive organ weights. Testes, seminal vesicles, epididymis + vas deferens. | DO population | m | 12-15wks | 2020 |
|
|
sperm count | Sperm count. Hemocytometer. | DO population | m | 12-15wks | 2020 |
|
|
body weight
with arsenic |
Baseline, then after iAs exposure for 26 wks | DO population | m | 4-34 wks | 2022 |
|
|
hormone quantification
with arsenic |
Blood insulin following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
intake monitoring
with arsenic |
Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolic panel
with arsenic |
Blood glucose following 6 h fast, and after intraperitoneal glucose injection; at baseline and after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolite quantification
with arsenic |
iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) | DO population | m | 4-34 wks | 2022 |
|
|
MRI
with arsenic |
Fat and lean tissue mass at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
urinalysis
with arsenic |
Urine volume at baseline, and 12 and 24 wks after iAs exposure | DO population | m | 4-34 wks | 2022 |